A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Respiratory Syncytial Virus Prefusion F Subunit Vaccine when Coadministered with Seasonal Inactivated Influenza Vaccine in Adults ≥65 Years of Age.
Year: 2022
Type: Vaccine
Phase: III
Indication: Healthy
A Phase 2, Randomized, Observer-Blinded Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle and Quadrivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine With Matrix-M™ Adjuvant in Healthy Participants ≥ 50 to ≤ 80 Years of Age.
Year: 2023
Type: Vaccine
Phase: II
Indication: Healthy
A Multicenter, Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly.
Year: 2019
Type: Vaccine
Phase: III
Indication: Healthy
A Randomized, Double-blind, Placebo-controlled Phase 2b Study to Assess the Efficacy, Immunogenicity and Safety of an Ad26.RSV.preF-based Regimen in the Prevention of RT-PCR-confirmed RSV-mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older.
Year: 2019
Type: Vaccine
Phase: IIb
Indication: Healthy
A Randomised, Double-Blinded Study to Assess Safety, Immunogenicity, and Lot Consistency of Solvay’s Cell Derived Influenza Vaccine.
Year: 2010
Type: Vaccine
Phase: III
Indication: Healthy
A Randomized, Observer-Blind with Single-Blind Booster, Multi Centre, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Adult and Elderly Subjects.
Year: 2013
Type: Vaccine
Phase: II
Indication: Healthy
A Phase 2b Study to Determine the Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults aged 18 years and over.
